company overview
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
leadership
Vik Bajaj
President
Vik serves as Director & Interim President of Xaira Therapeutics (jointly incubated by Foresite Labs and ARCH Venture Partners), among several other companies in the Foresite Labs and Capital portfolios, and is a Non-Executive Director of Genomics England.
A former academic principal investigator, Vik is now an adjunct Associate Professor at the Stanford University School of Medicine. His academic research interests lie at the interface of the physical sciences, engineering, and the life sciences.
He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology and a combined B.A./M.S. from the University of Pennsylvania.
investment date
September 2023
Industry
Biotechnology Research
headquarters
Brisbane, CA